OSTON — The metronomic rate of failure in Alzheimer’s disease can be crushing to scientists and bankrupting to industry. But when success is in such short supply, every little light through the cracks gets put through a kaleidoscope and parsed for signs of hope.

Such was the case at this year’s Clinical Trials in Alzheimer’s Disease conference, where an onslaught of negative studies got autopsied for lessons that might inform future trials — and signals that once-failed drugs may yet thrive.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.